Maddalena Ardissino

Maddalena Ardissino

Auto-generated profile, based on publicly available information

Maddalena Ardissino

Imperial College London

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SMSilvia Muttoni
Silvia Muttoni
MAMaddalena Ardissino
Maddalena Ardissino
CJChristopher John
Christopher John

20 September 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MAMaddalena Ardissino
Maddalena Ardissino
AMAlec P Morley
Alec P Morley
ESEric A W Slob
Eric A W Slob
ASArt Schuermans
Art Schuermans
BRBilal Rayes
Bilal Rayes
Fu Siong NgFu Siong Ng
Fu Siong Ng
Low birth weight is a common pregnancy complication, which has been associated with higher risk of cardiometabolic disease in later life. Prior Mendelian randomization (MR) studies exploring this question do not distinguish the mechanistic contributions of variants that directly influence birth weight through the foetal genome (direct foetal effects), vs. variants influencing birth weight indirectly by causing an adverse intrauterine environment (indirect maternal effects). In this study, MR was used to assess whether birth weight, independent of intrauterine influences, is associated with cardiovascular disease risk and measures of adverse cardiac structure and function. Uncorrelated (r2 < .001), genome-wide significant (P < 5 × 10−8) single nucleotide polymorphisms were extracted from genome-wide association studies summary statistics for birth weight overall, and after isolating direct foetal effects only. Inverse-variance weighted MR was utilized for analyses on outcomes of atrial fibrillation, coronary artery disease, heart failure, ischaemic stroke, and 16 measures of cardiac structure and function. Multiple comparisons were accounted for by Benjamini–Hochberg correction. Lower genetically-predicted birth weight, isolating direct foetal effects only, was associated with an increased risk of coronary artery disease (odds ratio 1.21, 95% confidence interval 1.06–1.37; P = .031), smaller chamber volumes, and lower stroke volume, but higher contractility. The results of this study support a causal role of low birth weight in cardiovascular disease, even after accounting for the influence of the intrauterine environment. This suggests that individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation. Mendelian randomization study evaluating the causal relevance of birth weight on cardiovascular structure function and disease risk. UKB, UK Biobank; EGG, Early Growth Genetics Consortium; MRI, magnetic resonance imaging.

7 March 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
MAMaddalena Ardissino
Maddalena Ardissino
ESeric slob
eric slob
PCPaul Carter
Paul Carter
TRTormod Rogne
Tormod Rogne
JGJoanna Girling
Joanna Girling
Fu Siong NgFu Siong Ng
Fu Siong Ng
Background: Observational studies suggest that reproductive factors are associated with cardiovascular disease, but these are liable to influence by residual confounding. This study explores the causal relevance of reproductive factors on cardiovascular disease in women using Mendelian randomization. Methods and Results: Uncorrelated ( r 2 <0.001), genome‐wide significant ( P <5×10 −8 ) single‐nucleotide polymorphisms were extracted from sex‐specific genome‐wide association studies of age at first birth, number of live births, age at menarche, and age at menopause. Inverse‐variance weighted Mendelian randomization was used for primary analyses on outcomes of atrial fibrillation, coronary artery disease, heart failure, ischemic stroke, and stroke. Earlier genetically predicted age at first birth increased risk of coronary artery disease (odds ratio [OR] per year, 1.49 [95% CI, 1.28–1.74], P =3.72×10 −7 ) heart failure (OR, 1.27 [95% CI, 1.06–1.53], P =0.009), and stroke (OR, 1.25 [95% CI, 1.00–1.56], P =0.048), with partial mediation through body mass index, type 2 diabetes, blood pressure, and cholesterol traits. Higher genetically predicted number of live births increased risk of atrial fibrillation (OR for 2 live births, 2.91 [95% CI, 1.16–7.29], P =0.023), heart failure (OR, 1.90 [95% CI, 1.28–2.82], P =0.001), ischemic stroke (OR, 1.86 [95% CI, 1.03–3.37], P =0.039), and stroke (OR, 2.07 [95% CI, 1.22–3.52], P =0.007). Earlier genetically predicted age at menarche increased risk of coronary artery disease (OR per year, 1.10 [95% CI, 1.06–1.14], P =1.68×10 −6 ) and heart failure (OR, 1.12 [95% CI, 1.07–1.17], P =5.06×10 −7 ); both associations were at least partly mediated by body mass index. Conclusions: These results support a causal role of a number of reproductive factors on cardiovascular disease in women and identify multiple modifiable mediators amenable to clinical intervention.

4 January 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
MAMaddalena Ardissino
Maddalena Ardissino
ESeric slob
eric slob
OMOphelia Millar
Ophelia Millar
RRRohin Reddy
Rohin Reddy
LLLaura Lazzari
Laura Lazzari
Fu Siong NgFu Siong Ng
Fu Siong Ng
Background: Maternal cardiovascular risk factors have been associated with adverse maternal and fetal outcomes. Given the difficulty in establishing causal relationships using epidemiological data, we applied Mendelian randomization to explore the role of cardiovascular risk factors on risk of developing preeclampsia or eclampsia, and low fetal birthweight. Methods: Uncorrelated single-nucleotide polymorphisms associated systolic blood pressure (SBP), body mass index, type 2 diabetes, LDL (low-density lipoprotein) with cholesterol, smoking, urinary albumin-to-creatinine ratio, and estimated glomerular filtration rate at genome-wide significance in studies of 298 957 to 1 201 909 European ancestry participants were selected as instrumental variables. A 2-sample Mendelian randomization study was performed with primary outcome of preeclampsia or eclampsia (PET). Risk factors associated with PET were further investigated for their association with low birthweight. Results: Higher genetically predicted SBP was associated increased risk of PET (odds ratio [OR] per 1-SD SBP increase 1.90 [95% CI=1.45–2.49]; P =3.23×10 −6 ) and reduced birthweight (OR=0.83 [95% CI=0.79–0.86]; P =3.96×10 −18 ), and this was not mediated by PET. Body mass index and type 2 diabetes were also associated with PET (respectively, OR per 1-SD body mass index increase =1.67 [95% CI=1.44–1.94]; P =7.45×10 −12 ; and OR per logOR increase type 2 diabetes =1.11 [95% CI=1.04–1.19]; P =1.19×10 −3 ), but not with reduced birthweight. Conclusions: Our results provide evidence for causal effects of SBP, body mass index, and type 2 diabetes on PET and identify that SBP is associated with reduced birthweight independently of PET. The results provide insight into the pathophysiological basis of PET and identify hypertension as a potentially modifiable risk factor amenable to therapeutic intervention.

19 January 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ANAdam James Nelson
Adam James Nelson
MAMaddalena Ardissino
Maddalena Ardissino
KHKevin Haynes
Kevin Haynes
SSSonali Shambhu
Sonali Shambhu
ZEZubin J. Eapen
Zubin J. Eapen
CGChristopher B. Granger
Christopher B. Granger
Background: Evidence‐based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results: Pharmacy and medical claims data from within Anthem were queried for patients with established atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Using an index date of April 18, 2018, we evaluated the proportion of patients with a prescription claim for any of the 3 evidence‐based therapies on, or covering, the index date ±30 days: high‐intensity statin, angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker, and sodium glucose cotransporter‐2 inhibitor or glucagon‐like peptide‐1 receptor agonist. The potential benefit of achieving 100% adoption of all 3 evidence‐based therapies was simulated using pooled treatment estimates from clinical trials. Of the 155 958 patients in the sample, 24.7% were using a high‐intensity statin, 53.1% were using an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker, and 9.9% were using either an sodium glucose cotransporter‐2 inhibitor or glucagon‐like peptide‐1 receptor agonists. Overall, only 2.7% of the population were covered by prescriptions for all 3 evidence‐based therapies, and 37.4% were on none of them. Over a 12‐month period, 70.6% of patients saw a cardiologist, while only 18% saw an endocrinologist. Increasing the use of evidence‐based therapies to 100% over 3 years of treatment could be expected to reduce 4546 major atherosclerotic cardiovascular events (myocardial infarction, stroke, or cardiovascular death) in eligible but untreated patients. Conclusions: Alarming gaps exist in the contemporary use of evidence‐based therapies in this large population of insured patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. These data provide a call to action for patients, providers, industry, regulators, professional societies, and payers to close these gaps in care.

13 September 2018 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
MAMaddalena Ardissino
Maddalena Ardissino
ATAlice Tang
Alice Tang
EMElisabetta Muttoni
Elisabetta Muttoni
KTKevin Tsang
Kevin Tsang
Introduction Paediatric traumatic brain injury (pTBI) is one of the most frequent neurological presentations encountered in emergency departments worldwide. Every year, more than 200,000 American children suffer pTBIs, many of which lead to long-term damage. Objectives We aim to review the existing evidence on the efficacy of the decompressive craniectomy (DC) in controlling intracranial pressure (ICP) and improving long-term outcomes in children with pTBI. Methods A comprehensive search of the MEDLINE and EMBASE databases led to the screening of 212 studies, 12 of which satisfied inclusion criteria. Data extracted included the number and ages of patients, Glasgow Coma Scale scores at presentation, treatment protocols and short- and long-term outcomes. Results Each of the nine studies including ICP as an outcome reported that it was successfully controlled by DC. The 6–12 month outcome scores of patients undergoing DC were positive, or superior to those of medically treated groups in nine of 11 studies. Mortality was compared in only two studies, and was lower in the DC group in both.Very few studies are currently available investigating short- and long-term outcomes in children with TBI undergoing DC. Conclusion The currently available evidence may support a beneficial role of DC in controlling ICP and improving long-term outcomes.